It is generally related to immunology and molecular biology. This document provides drug combinations including (a) antibodies.Or the binding part of their antigensFor Ly75,(b) The second anti-cancer entity；2. Nucleic acid encoded by combination of antibodies；2. The method of preparing antibody combination；And the treatment of diseases,For example, neutral cancer because of Ly75 performance or activity Requirement 1: Include (a) combination of anti-Ly75 antibodies.Or part of its antigenIt competes with an antibody that consists of a heavy chain variable region, including the amino acid sequence exposed in ID 1.It also includes a variable light chain region, including the amino acid sequence exposed in ID 2.Or anti-Ly75 antibodiesOr part of its antigenUnderstand this antibody: (a) a variable heavy chain region, including: (1) the first hexachlorobenzene composed of ID 5；(2) The second kind of hexachlorobenzene, including SEC ID No.6；(3) The third kind of hexachlorobenzene, including ID 7；(b) A light chain variable region, including: (1) the first VLCDR consisting of ID 8；(2) The second VLCDR, including SEC ID No.9；(3) The third VLCDR, including SEC ID 10；Alternative text: Any one or more of the above SEC forms an independent one.Two...Three...Four or five alternatives2. Amino acid addition or distribution；And (b) an anti-CD20 antibody or a part of the binding antigen,Understand this antibody: (a) a variable heavy chain region, including: (1) the first hexachlorobenzene composed of SEC number 40；(2) The second kind of hexachlorobenzene, including ID 41；(3) The third kind of hexachlorobenzene, including ID No. 42；(b) Light chain transformation region, including: (1) the first VLCDR, including SEC ID No. 43；(2) The second VLCDR includes ID No. 44；(3) The third VLCDR, including ID No. 45；Alternative text: Any one or more of the above SEC forms an independent one.Two...Three...Four or five alternatives2. Amino acid addition or distribution；Where the combination of drugs i
